Posaconazole: clinical pharmacology and potential for management of fungal infections.
about
The challenge of managing fusariosisTreatment of invasive infections due to rare or emerging yeasts and moulds.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.Posaconazole: a new broad-spectrum antifungal agent.Fosamprenavir calcium plus ritonavir for HIV infection.Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Clinical pharmacology of antifungal agents in pediatric patients.Posaconazole in the management of refractory invasive fungal infections.Antifungal agents--clinical pharmacokinetics and drug interactions.Antifungal therapies in the intensive care unit.Fusarium keratitis and contact lens wear: facts and speculations.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.Antifungal therapy in children: an update.Antifungal agents in current pediatric practice.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Susceptibility pattern of Candida albicans isolated from Iranian patients to antifungal agents.Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.Reverse masquerade syndrome: fungal adnexal infection mimicking carcinoma in a HIV-positive patient.Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Synthesis and in vitro and in vivo antifungal activity of the hydroxy metabolites of saperconazole.Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles.Structure prediction of gBP21 protein of L. donovani and its molecular interaction.Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
P2860
Q35693680-5B189441-D277-4AD7-9798-0EBD7FB787FFQ36491806-62D23310-2C04-40F3-90AC-43B15C3ADED0Q36491819-111BA88E-CF54-41C5-9A6E-CC44ABD1376EQ36589292-02CED9B1-49FD-471B-B85C-2DE26116E8A3Q36589297-B0211526-945C-4F56-97F9-7C1CEC8B89B9Q36828159-B9E17F1C-565A-4624-A434-3AAC963DE3BCQ36839698-5D09DEB3-849D-47EE-A8A4-0E89FE334CBAQ36862446-E44F34EC-63D6-4F05-BE37-6CFD6C33ABA2Q36968140-E94717C7-4EDC-479C-AC42-057B8CAA2F76Q37052755-C51FEC07-2E4D-4BEE-9C83-3C28E8C5A551Q37159568-7124CC02-4C05-478E-8DCB-32D11E0ACF9CQ37161793-2172CA9C-000F-41FA-975F-79E33BE31075Q37209944-C457DAA7-ABAB-477E-ADF0-4A143461F231Q37404840-E753EE18-AA59-4595-9035-B5CADD6D3AF5Q37761047-9663D82B-FC97-46FC-B043-9825408FE338Q38015090-DC37D898-49DC-4BF1-A038-08ACFF01C751Q38101520-E63C330E-174D-4B78-89E3-96F0CAD19CEAQ38681635-C67F9B77-C8FF-4BCF-A435-934AC08B8F8AQ38691900-2EC1EC72-1304-4079-A3EB-42ACEB56D1C1Q38786258-E889DF05-FDF7-4BEB-84AB-0A6DAC41B1E3Q40309090-7BED7286-AC44-4A76-939F-C0F9AAC6C157Q41284722-A846A81E-F671-4505-B860-BAACBAB00642Q41842788-64906A69-D3E5-4B20-9F1C-1E9D2C9EADD1Q41863584-7C1948DC-67A1-4705-BB0A-EF464134C55BQ42956812-35275E02-48F3-4D25-BFCC-B3D00DE11FBBQ43105019-A30020C0-473C-4064-B6C0-1296B6553F43Q44968373-CA3FDCDE-DA7D-4563-921E-8CC8CBE49537Q46148191-2AA43ABC-D625-4FE7-A356-D4047DBA68A4Q47618244-12876E49-E808-4AF7-BF27-D3C2117EBE28
P2860
Posaconazole: clinical pharmacology and potential for management of fungal infections.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@ast
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@en
type
label
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@ast
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@en
prefLabel
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@ast
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@en
P2860
P356
P1476
Posaconazole: clinical pharmacology and potential for management of fungal infections.
@en
P2093
Andreas H Groll
Thomas J Walsh
P2860
P304
P356
10.1586/14787210.3.4.467
P577
2005-08-01T00:00:00Z